Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)

Launched by INNA CHEN, MD · Oct 30, 2020

Keywords

ClinConnect Summary

The BetterEveryDay trial is designed to help improve the care and quality of life for patients with advanced pancreatic or biliary tract cancer. This study focuses on understanding how these patients feel during their treatment by collecting their feedback on symptoms and challenges they face. The goal is to find ways to reduce unexpected hospital visits and enhance overall treatment outcomes, as these cancers often lead to significant physical and emotional suffering.

To be eligible for this study, participants need to be at least 18 years old and have a confirmed diagnosis of advanced lung (non-small cell lung cancer) or pancreatic cancer. They should be planning to start their first round of cancer treatment within two weeks and must be able to read and respond to questions, either on their own or with minimal help. Participants will be asked to share their experiences, which will help researchers develop better support and care strategies tailored to their needs. It's important to note that those with significant mental health issues or participating in conflicting studies may not be eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult (aged 18 and over)
• • Confirmed by cytology or histology advanced lung (NSCLC) or pancreatic cancer
• • Written informed consent before any study procedures
• • Planning to receive 1st line systemic anticancer therapy within ≤2 weeks
• • Performance status: ECOG 0-2
• • Access to the internet
• • Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member
• Exclusion Criteria:
• • No mobile device
• • Exhibiting signs of overt psychopathology or cognitive dysfunction
• • Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments
• • Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.